Bioiberica to present two innovative products for joint and tendon health at Vitafoods Europe 2018
- Articolageno® Caps and Tendoactive® will be the company's main novelties at Europe's largest nutraceuticals event
- New evidence for the therapeutic potential of chondroitin sulfate and glucosamine in muscle injuries will also be presented
- Bioiberica has over 40 years’ experience in the research and development of nutritional ingredients and food supplements to improve joint health
Bioiberica (stand F50) will present two food supplements for joint and tendon health at Vitafoods Europe 2018, to be held in Geneva (Switzerland) from 15 to 17 May.
Articolageno® Caps is an innovative formula combining b-2cool® and Mobilee® (two Bioiberica joint health branded ingredients), along with vitamins, in a single product. b-2cool® is a native type II collagen-based natural ingredient that helps maintain joint health thanks to its immune-mediated mechanism of action. And Mobilee® is a patented ingredient rich in hyaluronic acid which contributes to maintain joint function.
“The presentation at Vitafoods of this new product, planned to launch at the end of the year, is a major opportunity to promote our dedicated joint health and mobility range of nutritional ingredients and supplements. We remain committed to quality products based on innovation and scientific evidence,” said Bioiberica Human Health International director, Jaume Reguant.
In addition, the benefits of Tendoactive®- a food supplement specific for tendons that contains type I hydrolysed collagen, mucopolysaccharides, vitamin C and manganese- will be presented. Marta Masides, head of Product Support at the Bioiberica R&D Department, will give a talk entitled “Innovative Approach to Tendon Health” at the Sports Nutrition Zone Theatre (16 May 12.20 pm). Different scientific studies have shown that oral supplements in the form of Tendoactive® represent a new approach to supporting tendon health from a nutritional perspective and as a complement to physical therapy.
The company will also present a scientific paper in the Posters’ Area on the therapeutic potential of chondroitin sulphate and glucosamine in muscle injuries, a preclinical study in human muscle cells which clarifies the action mechanisms involved in the positive effects of pharmaceutical-grade chondroitin sulphate and glucosamine.
Bioiberica is a global company specialising in the research, production and sale of biomolecules such as chondroitin sulphate, glucosamine, heparin and hyaluronic acid. Since 1975, Bioiberica has consolidated its position as an international leader in joint health and chondroprotection through constant dedication and commitment to science and research. Vertically integrated from active ingredient to final product, Bioiberica places all its medical, scientific and marketing knowledge at the client’s disposal for joint market development.
